NEW YORK (GenomeWeb News) – Exact Sciences will meet next week with officials from the Centers for Medicare and Medicaid Services to discuss the status of CMS’ review of the firm’s colorectal cancer screening technology, the company said today.
 
The company applied last August for a national coverage determination with CMS to try to get the stool-based CRC diagnostic covered under Medicare, but in October it was notified by the US Food and Drug Administration that the PreGen-Plus assay would require premarket approval.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.